H.R. 8774 — Introduced in House

I 117th CONGRESS 2d Session H. R. 8774 IN THE HOUSE OF REPRESENTATIVES September 6, 2022Mr. McKinley (for himself and Mrs. Axne) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To require the Director of the National Institutes of Health to conduct an evaluation of menopause-related research (including gaps in research and knowledge regarding the causes, symptoms, and treatments for menopause), to develop a strategic plan to resolve gaps in knowledge and research, and identify topics in need of further research relating to potential treatments for menopause-related symptoms, and for other purposes. 1. Short title This Act may be cited as the Menopause Research Act of 2022. 2. Evaluation of menopause-related research (a) In general The Director of the National Institutes of Health shall— (1) conduct an evaluation of— (A) the results of completed menopause-related research, and research on mid-life women’s health; (B) the status of ongoing menopause-related research, and research on mid-life women’s health; and (C) any gaps in knowledge and research on— (i) treatments for menopause-related symptoms; and (ii) the safety and effectiveness of treatments for menopause-related symptoms; and (2) as part of such evaluation, identify the total amount of funding allocated by the National Institutes of Health for the conduct or support of menopause-related research, and research on mid-life women’s health over the preceding 5 fiscal years. (b) Report; strategic plan Not later than 180 days after the date of enactment of this Act, the Director of the National Institutes of Health shall submit to the Congress— (1) a report on the findings of such evaluation; and (2) a strategic plan— (A) to resolve the gaps in knowledge and research identified in the report; and (B) to identify topics in need of further research relating to potential treatments for menopause-related symptoms. 3. Menopause-related research, and research on mid-life women’s health (a) In general The Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, shall conduct or support menopause-related research, and research on mid-life women’s health. (b) Authorization of appropriations There is authorized to be appropriated to carry out this section $100,000,000 for each of fiscal years 2023 and 2024.